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ABSTRACT Connector enhancer of KSR (CNK) is a
multidomain protein that participates in Ras signaling
in Drosophila eye development. In this report we iden-
tify the human homologue of CNK, termed CNK2A,
and a truncated alternatively spliced variant, CNK2B.
We characterize CNK2 phosphorylation, membrane
localization, and interaction with Ras effector mole-
cules. Our results show that MAPK signaling appears to
play a role in the phosphorylation of CNK2 in vivo.
CNK2 is found in both membrane and cytoplasmic
fractions of the cell. In MDCK cells, full-length CNK2 is
localized to the lateral plasma membrane. Consistent
with previous reports, we show CNK2 interacts with
Raf. CNK2 interaction was mapped to the regulatory
and kinase domains of Raf, as well as to the carboxyl-
terminal half of CNK2. CNK2 also interacts with the
Ral signaling components, Ral GTPase, and the Ral-
GDS family member Rlf. CNK2 interaction was
mapped to the GEF domain of Rlf. The ability of CNK2
to interact with both Ras effector proteins Raf and Rlf
suggests that CNK2 may integrate signals between
MAPK and Ral pathways through a complex interplay
of components.—Lanigan, T. M., Liu, A., Huang, Y. Z.,
Mei, L., Margolis, B., Guan, K.-L. Human homologue
of Drosophila CNK interacts with Ras effector proteins
Raf and Rlf. FASEB J. 17, 2048–2060 (2003)
The small GTPase Ras oncogene is central in inte-
grating and transmitting extracellular signals to a vari-
ety of cellular processes such as proliferation, differen-
tiation and survival through downstream signaling
pathways (1, 2). Ras controls these pathways by directly
interacting with "effector" proteins, which then activate
specific downstream pathways. Numerous putative Ras
effectors have been identified, but Raf kinase, PI3
kinase, and the family of Ral GTP exchange proteins
called RalGDS have been shown to be involved in Ras
signaling (1, 2). Raf kinase activates the mitogen-
activated protein kinase (MAPK) cascade that controls
cell proliferation and differentiation. Genetic studies in
Caenorhabditis elegans and Drosophila show that Raf plays
a major role in Ras signaling (3, 4). PI3 kinase seems to
mediate some of the Ras-dependent actin cytoskeleton
remodeling, protection against apoptosis and onco-
genic transformation. Last, RalGDS activates the Ral
GTPase protein that regulates multiple pathways in-
cluding receptor endocytosis, cytoskeletal changes, and
DNA synthesis. Recently a number of proteins have
been identified by genetic studies that appear to mod-
ulate Ras signaling in the cell. These modulators in-
clude kinase suppressor of Ras (KSR), suppressor of Ras
(SUR-8), and connector enhancer of KSR (CNK). KSR
was identified in both Drosophila and C. elegans as a
positive regulator for MAPK signaling (5–7). Epistatic
studies place KSR upstream or parallel to Raf. KSR is
structurally similar to Raf kinase. Biochemical studies
have shown that KSR interacts with components of the
MAPK signaling pathway and may act as a scaffolding
protein (8–11). Another modulator of Ras signaling is
SUR-8, originally identified in C. elegans. Epistatic stud-
ies placed SUR-8 downstream or parallel to Ras (12).
Biochemical studies have shown that mammalian
SUR-8 enhances suboptimal stimulation of Ras and
interacts with Ras and Raf simultaneously (13). It is
possible that KSR and SUR-8 act in tandem to bring Ras
and the MAPK signaling components together upon
cell stimulation. Biochemical studies have also identi-
fied MP-1 as a positive modulator of the MAPK cascade
(14). MP1 was shown to interact with MEK and ERK.
These data indicate that the MAPK pathway may be
modulated by multiple scaffold-like proteins. CNK was
identified in Drosophila eye development by genetic
screens designed to identify genes involved in KSR
function (15). A dominant-negative KSR mutant caused
a slight rough eye phenotype due to blocking Ras-
dependent photoreceptor cell differentiation. A loss-of-
function CNK mutation enhanced the rough eye phe-
notype, suggesting its role as a positive regulator in Ras
signaling. The deduced CNK sequence contains several
putative protein–protein binding domains but none
containing known enzymatic functions. This has led to
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the hypothesis that CNK may function as an adaptor
molecule, similar to KSR and SUR-8. Consistent with
this notion, down-regulation of CNK1 in Drosophila S2
cells leads to decrease of ERK activation (16). Epistatic
studies place CNK upstream or parallel to Raf in eye
development (15). Overexpression of wild-type CNK
enhances signaling of activated Ras, but attenuates
activated Raf. The finding that CNK interacts with Raf
supports the premise that CNK regulates Raf function
in some capacity, but it is likely that CNK acts through
additional Ras signaling pathways (15, 17). Further-
more, CNK positively acts in a cooperative fashion with
Ras effector loop mutant RasV12G37, which selectively
activates the Ral pathway (18), but not with effector
loop mutants that activate MAPK or PI3K pathways (18,
19), suggesting that CNK may modulate the Ral path-
way in Drosophila (17). The rat homologue of CNK,
membrane-associated guanylate kinase-interacting pro-
tein (MAGUIN-1), was identified in two-hybrid screens
using domains of the neuronal membrane-associated
guanylate kinase protein synaptic scaffolding molecules
(S-SCAM) as bait (20). An alternatively spliced trun-
cated form was identified, named MAGUIN-2, which
lacks the carboxyl-terminal region of MAGUIN-1.
MAGUIN-1 was shown to have neural-specific expres-
sion and to coimmunoprecipitate with postsynaptic
density (PSD) 95/synapse-associated protein (SAP) 90
and S-SCAM from rat synaptosomes. MAGUIN-1 was
also shown to interact with Raf kinase suggesting a
functional homologue of CNK (21). However,
MAGUIN-1 did not affect Raf kinase activity or Raf
translocation. We identified the human homologue of
CNK (termed CNK2A) and an alternatively spliced
truncated version, CNK2B. In this report, we character-
ize CNK2 phosphorylation, membrane localization,
and Raf interaction. Overexpression of CNK2 inhibits
MAPK signaling. CNK2 interacts with the Ras effector
protein Rlf, a RalGDS homologue, and the Ral GTPase
protein, both components of the Ral signaling pathway.
Overexpression of CNK2 did not significantly activate
Ral or cause Rlf to translocate to the membrane. Taken
together, these results suggest that CNK2 is a functional
homologue of Drosophila CNK that interacts with Ras
effector proteins. We propose CNK2 may function as an
adaptor protein or regulator of multiple Ras signaling
pathways.
MATERIALS AND METHODS
Plasmid construction
CNK2 was isolated from a fetal human brain cDNA/lambda
ZAPII library (Stratagene, San Diego, CA, USA) using stan-
dard library hybridization screening techniques as described
in the manual (Stratagene). The human EST R13297, which
shares sequence similarity with the Drosophila cDNA based on
computer search analysis, was used as a probe in the screen.
Several overlapping cDNAs were isolated, sequenced, and
used to construct the full-length CNK2 cDNA. The full-length
CNK2 cDNA was then subcloned into hemagglutinin antigen
(HA) -tagged mammalian expression vector pcDNA3 (22)
and FLAG-tagged pcDNA3 (23). CNK2-N-term consisting of
residues 1 to 405 was subcloned into HA-pcDNA3 and FLAG-
pcDNA3 vectors. CNK2A-C-term and CNK2B-C-term consist-
ing of residues 389 to 1034 and 389 to 899, respectively, were
subcloned into HA-pcDNA3 and pGEX-KG (24) vectors.
HA-Ral (25) and HA-Rlf (26) were generously provided by Dr.
J. Bos (Utrecht University). HA-Rlf N-term, HA-Rlf-GN, and
HA-Rlf-GEF consisting of residues 1 to 527, 1 to 213, and 218
to 528, respectively, were subcloned into HA-pcDNA3 vector.
FLAG-C-Raf was generously provided by Dr. Kevin Pumiglia
(University of Michigan), while B-Raf and HA-C-Raf con-
structs were generously provided by Dr. A. Vojtek (University
of Michigan). B-Raf was subsequently cloned into HA-tagged
mammalian expression vector pcDNA3. FLAG-C-Raf 1-269 aa
and FLAG-C-Raf 325-648 aa were constructed by deleting
residues 270-649 and 1-324, respectively, from FLAG-C-Raf.
FLAG-p85 and HA-p110 (27) were generously provided by Dr.
E. Skolnik (New York University). FLAG-SOS (28), HA-
smgGDS, HA-SUR8 (13), and FLAG-FKHR (29) were gener-
ously provided by Dr. J. Pessin (University of Iowa), H. Vikis
(University of Michigan), Dr. Q. Li (University of Michigan),
and E. Tang (University of Michigan), respectively. DNA
constructs KRasV12, myc-ERK, Gal4-Elk, Gal4-LUC, myc-KSR,
and pCMV-lacZ have been described (22).
Cell culture and transfection
HEK293 and MDCK cells were cultured in Dulbecco’s modi-
fied Eagle’s medium (DMEM) containing 10% fetal bovine
serum (FBS), penicillin (100 units/mL), and streptomycin
(100 g/mL). NIH3T3 cells were cultured the same as
HEK293 cells, except 10% calf serum was used in place of
FBS. HEK293 cells and NIH3T3 cells were transfected using
the LipofectAMINE (Life Technologies, Inc., Grand Island,
NY, USA) method and MDCK cells were transfected using
Fugene 6 (Roche) method, both as recommended by the
manufacturer.
In vitro kinase assays
HEK293 cells were transfected with 100 ng Myc-ERK, 10 ng
K-RasV12, or 50–250 ng HA-CNK2B, as indicated. Cells were
maintained in 10% FBS medium for 24 h and starved in 0.1%
FBS for 15 h. Cells were lysed in RIPA lysis buffer (50 mM
tris-HCl pH7.5, 150 mM NaCl, 1% Triton 100, 0.5% deoxy-
cholate, 1 mM DDT, 50 mM NaF, 1 mM EDTA, 1 mM EGTA,
1 mM PMSF, 10 g/mL leupeptin, 10 g/mL aprotinin) and
Myc-ERK was immunoprecipitated with monoclonal antibody
9E10 (anti-myc, BABCO, Richmond, CA, USA) and protein
G-Sepharose. The immunocomplexes were then washed and
assayed for 20 min at 30°C in kinase assay buffer containing
10 Ci of [-32P]-ATP and 1 g GST-Elk. GST-Elk were
expressed in Escherichia coli and purified as described previ-
ously (22).
Coimmunoprecipitation and pull-down analysis
For all but the Ral coimmunoprecipitation experiments,
HEK293 cells grown in 6-well plates were transfected with 0.5
g of each plasmid and equalized with empty vector. Forty-
eight hours after transfection, cells were treated with 25
ng/mL EGF (where applicable), lysed in NP-40 buffer (10
mM tris-HCl pH7.5, 100 mM NaCl, 1% Nonidet P40, 50 mM
NaF, 2 mM EDTA, 1 mM PMSF, 10 g/mL leupeptin, 10
g/mL aprotinin), and immunoprecipitated with either anti-
M2 or anti-HA (BABCO) antibodies and protein-G Sepharose
beads. Glutathione-coupled beads were used in the pull-down
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assay to purify GST fusion protein complexes. In the HA-Ral
coimmunoprecipitation experiment, HEK293 cells were
transfected with 10 ng K-RasV12, 100 ng HA-Rlf, 250 ng
FLAG-CNK2, and 500 ng HA-Ral. In the endogenous Ral
coimmunoprecipitation experiment, the brain from a 6-wk-
old rat was homogenized in a Dounce homogenizer. In both
Ral experiments, the cells were resuspended in lysis buffer
(20 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 , 5%
glycerol, 1% Triton 100, 1 mM PMSF, 10 g/mL leupeptin,
10 g/mL aprotinin) and immunoprecipitated as above
using either anti-M2 (Sigma, St. Louis, MO, USA anti-tuberin
(Santa Cruz, Santa Cruz, CA, USA), or anti-Maguin N-term
(generously provided by Y. Takai) and protein-G Sepharose
beads. The complexes were resolved by SDS-PAGE and trans-
ferred onto PVDF membranes. The precipitated proteins
were detected with anti-HA, 9E10 antibody (anti-myc), anti-
MEK (30), anti-GST (Zymed, San Francisco, CA, USA),
anti-C-Raf (Transduction Laboratories, Lexington, KY, USA),
anti-Ral (Transduction Laboratories), and anti-Maguin N-
term antibodies.
Immunoblot analysis with anti-phospho antibodies and
fractionation experiments
HEK293 cells were transfected with 0.5 g of each plasmid
unless otherwise noted. In experiments using anti-phospho
antibodies, transfected cells were maintained overnight in
10% FBS medium and starved in 0.1% FBS for 3 h prior to cell
lysis with RIPA buffer. In some cases, cells were treated with
25 ng/mL EGF, neuregulins, or 0.1 mM pervanadate (2
L/mL of 50 mM metavanadate, 50 mM H2O2, made fresh)
5–10 min prior to cell lysis. HA-CNK2B and FLAG-ERK were
immunoprecipitated as mentioned above, resolved by SDS-
PAGE, and transferred to PVDF membranes. Membranes
were blotted with anti-tyrosine or an anti-phospho-ERK spe-
cific antibody (Promega, Madison, WI, USA). In the fraction-
ation experiment, cells were resuspended in PBS containing 1
mM PMSF, 10 g/mL leupeptin, 10 g/mL aprotinin and
lysed by sonication. The insoluble material was pelleted from
cell lysate by centrifugation for 10 min at 8000  g and then
membranes were pelleted from lysate by ultracentrifugation
for 40 min at 100,000  g. The cytosol was removed and the
membranes resuspended in RIPA buffer at equal volume with
cytosol. The membranes and cytosol were resolved and blot-
ted as described above.
In vivo 32P-labeling
HEK293 cells were transfected with 0.5 g HA-CNK2A and 50
ng KRasV12 as indicated; 36 h after transfection, cells were
washed twice with phosphate-free medium and incubated
with 0.5 mCi/mL 32P-labeled inorganic 32P (ICN, Irvine, CA,
USA) at 37°C for 4 h. Cells were treated with 50 M Mek
inhibitor 098059 (Calbiochem, San Diego, CA, USA) or 50
M PI3K inhibitor ly294002 (Calbiochem) for 30 min prior to
cell lysis. Cells were washed with PBS extensively and lysed in
RIPA buffer. The HA-CNK2A was immunoprecipitated, re-
solved on SDS-PAGE and transferred to a membrane. Phos-
phorylated HA-CNK2B was exposed to a PhosphorImager.
Reporter Analysis
Luciferase reporter analysis was performed as described (22).
HEK293 cells were cotransfected with 25 ng Gal4-Elk1, Gal4-
luciferase (Gal4-LUC), and pCMV-lacZ, 5 ng KRasV12, 100 ng
HA-CNK2B, HA-CNK2-N-term, and HA-smgGDS, or 500 ng
HA-CNK2A; 24 h after transfection the cells were harvested
and assayed. Luciferase activity was determined and normal-
ized against the cotransfected -galactosidase activity as de-
scribed in figure legends and elsewhere (22).
Transformation assays
Cell transformation was assessed by focus formation assay.
NIH3T3 mouse fibroblasts were cotransfected with 10–25 ng
HRasV12, 50–100 ng pCMV-lacZ gene, and 250–500 ng
CNK2 constructs; 24 h post-transfection, cells were trypsinized
and 1/10th of the cells were taken for -galactosidase activity
assay to check the transfection efficiency among culture
plates. The remaining cells were plated onto 10 cm dishes and
maintained in 5% calf serum medium with medium change
every 3 days; 14 days later, cells were stained with crystal
violets and the number of transformed foci was counted.
Immunofluorescence
MDCK cells were cultured on 60 mm plates and transfected
with 3 g HA-tagged CNK2A, CNK2B, or CNK2 constructs;
48 h post-transfection, cells were trypsinized and plated onto
10 cm dishes and stable cells were selected with media
containing 500 g/mL G418 (Roche). Five days after selec-
tion, the cells were cultured on glass coverslips to near
confluency. Cells were then washed in PBS, fixed with 4%
paraformaldehyde, permeablized with 0.1% Triton 100 in
PBS with 2% goat serum, and blocked with goat serum. Cells
were incubated with either mouse anti-HA (BABCO) or rat
anti-HA (Roche) antibody, followed by incubation with an
anti-rat or anti-mouse IgG Texas red conjugated (Jackson
ImmunoResearch Laboratories, Inc., West Grove, PA, USA).
myc-PASL 1 A deletion was generously provided by Dr. B.
Margolis (University of Michigan). Myc-PALS A deletion was
stained with anti-myc antibody (9E10) and goat anti-mouse
IgG-FITC conjugated (Jackson ImmunoResearch Laborato-
ries, Inc.). Fluorescent cells were viewed with an inverted
fluorescent microscope (Leica) or imaged using a confocal
fluorescent microscope (Noran OZ Confocal Laser Scanning
Imaging System).
Ral-GTP pull-down assay
HEK293 cells were cultured in 6-well plates and transfected
with 500 ng HA-Ral, 10–250 ng HA-Rlf, 100–500 ng HA-
CNK2A, or 50 ng K-RasV12. The cells were harvested and
Ral-GTP isolated essentially as described (31). RalBD contain-
ing amino acids 397 to 518 of human RLIP76 was obtained
using RT-PCR techniques and cloned into pGEX-KG vector
(24).
RESULTS
Isolation of human CNK2
Genetic data implicate a role of CNK in Ras signaling.
Previous biochemical studies have shown that CNK is a
tyrosine phosphorylated, membrane localized protein
and can interact with Drosophila Raf (D-Raf) (15). Surpris-
ingly, the human homologue of CNK, CNK1, identified
by Therrien et al. (15) was not capable of interacting with
Raf kinase. This observation leads us to speculate that the
isolated human CNKs are not the functional homologue
of the Drosophila CNK. Using human EST sequences with
homology to CNK as probes, we screened a human fetal
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brain cDNA library. From these screens we obtained two
cDNA clones with homology to CNK, termed CNK2A and
CNK2B (Fig. 1). The predicted protein product of
CNK2A is 1034 amino acids; an alternatively spliced
truncated form (CNK2B) consists of 899 amino acids. The
putative protein–protein binding domains SAM, CRIC,
PDZ, and PH of CNK are all conserved in CNK2 with a
higher degree of homology than that of human CNK1
when compared with Drosophila CNK (Fig. 1). This obser-
vation indicates that CNK2 may be the functional homo-
logue of Drosophila CNK. CNK2A has a carboxyl terminus
PDZ binding motif that is not present in CNK2B or CNK.
We also isolated an alternatively spliced form of CNK2
that is missing part of the PDZ domain (Fig. 1). This
predicts that the alternative splicing form of CNK2 has a
nonfunctional PDZ domain that cannot interact with
target proteins containing PDZ binding sites, therefore
suggesting a potentially different function. CNK2A and
CNK2B have amino acid sequences nearly identical to rat
MAGUIN-1 and MAGUIN-2, respectively. We termed our
genes after CNK to keep in step with the previously
identified human homologue CNK1.
MAPK pathway dependent phosphorylation of CNK2
We predicted a functional homologue of CNK would
be a membrane-bound phosphoprotein capable of
interacting with Raf kinase. Therefore, we asked
whether CNK2 was phosphorylated in vivo. Since CNK
was shown to be tyrosine phosphorylated in a receptor
tyrosine kinase-dependent manner (15), we tested
CNK2 for tyrosine phosphorylation. HA-CNK2B was
expressed in HEK293 cells. Before cell lysis, cells were
treated with EGF to stimulate receptor tyrosine kinases
or pervanadate to block all tyrosine phosphatases.
HA-CNK2B was immunoprecipitated from the cell ly-
sate and immunoblotted with anti-phosphotyrosine
(Fig. 2A). We found that tyrosine phosphorylation of
CNK2B could be detected only when the cells were
pretreated with pervanadate. In the absence of pervana-
date, tyrosine phosphorylation was not observed even
when cells were treated with EGF, although EGF stim-
ulation of ERK was observed (data not shown).
We also tested CNK2 phosphorylation by an in vivo
labeling assay. HA-CNK2A was expressed in HEK293
Figure 1. Schematic representation of hu-
man CNK2. Homologues of CNK2 have
been identified across species from Dro-
sophila (CNK), C. elegans (Cel R01H10.8),
and mammals (hCNK1, CNK2, and
MAGUIN; not shown). The numbers of
the last amino acid residues are shown on
the right. The conserved SAM, CRIC,
PDZ, and PH domains are represented
with shaded boxes and indicated above.
An asterisk represents a PDZ binding site
present in CNK2A. Amino acid identity
percentage of the conserved domains
compared with CNK is shown. Alterna-
tively spliced variants of CNK2 that remove part of the PDZ domain is shown. Accession numbers for CNK2A and CNK2B
are AF418269 and AF418270, respectively.
Figure 2. CNK2 phosphorylation in HEK293 cells. A) Ty-
rosine phosphorylation of CNK2B from cells pretreated
with pervanadate. HA-CNK2B was expressed for 24 h, then
starved in 0.1% FBS for overnight. Before lysis, cells were
treated with EGF (25 ng/mL) for 5 min or with pervana-
date (pV) for 30 min, as indicated. HA-CNK2B was then
immunoprecipitated with anti-HA, resolved by SDS poly-
acrylamide gel, and immunoblotted with anti-phospho-
tyrosine. B) In vivo phosphorylation of CNK2A by Ras-
stimulated signaling pathways. Expression of CNK2A in the
presence or absence of RasV12 for 20 h. 4 h before lysis,
media was changed to serum-free conditions minus phos-
phate and supplemented with 0.5 Ci/mL inorganic 32P;
30 min prior to lysis, the cells were treated with MEK
inhibitor (MI) or PI3K inhibitor (PI). After lysis, HA-
CNK2A was immunoprecipitated and resolved on SDS
polyacrylamide gel, blotted, and exposed on a Phosphor-
Imager. The blot was subsequently immunoblotted with
anti-HA as shown.
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cells in the presence or absence of constitutively active
RasV12. The Ras signaling pathways MAPK and PI3K
were blocked with the addition of a MEK inhibitor (MI)
and a PI3K inhibitor (PI), respectively, prior to cell
lysis. HA-CNK2A was immunoprecipitated and incorpo-
ration of radiolabeled phosphate shown (Fig. 2B, upper
panel). As a control, the amount of HA-CNK2A was
determined with an immunoblot using anti-HA (Fig.
2B, lower panel). It is clear that CNK2A is phosphory-
lated in vivo. The MEK inhibitor reduced phosphory-
lation of CNK2A twofold when normalized to protein
levels (compare lanes 3 and 4). PI3K inhibitor had no
significant effect on CNK2A phosphorylation (compare
lanes 3 and 5). These results suggest that CNK2 is
phosphorylated by some factor downstream of MEK
and that the MAP kinase signal transduction pathway
plays a role in CNK2 phosphorylation.
CNK2 interacts with Raf but not MEK, KSR, or SUR8
To test whether CNK2 interacts with Raf kinase and
other components of Ras signaling, coimmunoprecipi-
tation experiments were performed with proteins
known to be involved in the MAPK pathway. HEK293
cells were cotransfected with epitope-tagged CNK2B
and either FLAG-C-Raf, MEK, myc-KSR, or HA-SUR8
(Fig. 3). Immunoprecipitation of HA-CNK2B was able
to copurify FLAG-C-Raf (Fig. 3A). Stimulation of the
MAPK pathway with EGF does not affect the interaction
between HA-CNK2B and FLAG-C-Raf. Similarly, immu-
noprecipitation of FLAG-C-Raf was able to copurify
HA-CNK2B (data not shown). There was no difference
detected in the ability of CNK2A or CNK2B to interact
with either C-Raf or B-Raf, suggesting a conserved
region of interaction between these proteins (data not
shown). However, immunoprecipitation of epitope-
tagged CNK2B does not appear to copurify MEK,
myc-KSR, or HA-SUR8 (Fig. 3B). Preliminary data sug-
gest that CNK2B cannot coimmunoprecipitate Ras or
ERK (data not shown). These results suggest that CNK2
interaction is specific for Raf kinase.
To map the regions of interaction in C-Raf and
CNK2, domains of each protein were expressed and
assayed for interaction by coimmunoprecipitation assay
in HEK293 cells (Fig. 4A). Immunoprecipitation of
HA-CNK2B was able to copurify both FLAG-Raf-1-269
(regulatory domain) and FLAG-Raf-325-648 (kinase
domain) (Fig. 4B). It was previously reported that
MAGUIN-1 interacts with the kinase domain of C-Raf
(21). We confirm this observation and extend these
findings to show that CNK2 also interacts with the
regulatory domain of C-Raf. To further map the regions
of interactions, various deletion mutants of the C-Raf
regulatory domain were coexpressed with a GST-
CNK2B-C-term fusion construct in HEK293 cells and
assayed for binding by pull-down experiment (Fig. 4C).
The regulatory and catalytic domains of C-Raf were
pulled down with the carboxyl-terminal part of CNK2B.
However, it appears that an intact regulatory domain is
required for full interaction with CNK2 (Fig. 4C).
Overexpression of CNK2 inhibits MAPK signaling
Using several approaches, we tested whether CNK2
mediates MAPK signaling. Using ERK activity as a
readout for Ras signaling, HEK293 cells were trans-
fected with HA-ERK, RasV12 and increasing amounts of
Figure 3. FLAG-C-Raf, but not MEK, myc-KSR, or HA-SUR8 coimmunoprecipitates with CNK2B. A) FLAG-C-Raf and HA-CNK2B
are expressed either together or independently in HEK293 cells for 48 h and treated with EGF 5 min prior to lysis. HA-CNK2B
was immunoprecipitated by anti-HA. The precipitates and cell lysate were resolved by SDS polyacrylamide gel and immuno-
blotted with anti-FLAG. The immunoblot was then stripped and reprobed with anti-HA. B) HA-CNK2B was expressed as in panel
A with either MEK or myc-KSR. FLAG-CNK2B was expressed with HA-SUR8. CNK2B was immunoprecipitated with anti-HA or
anti-FLAG. Precipitates and cell lysates were resolved as in panel A and immunoblots were probed with anti-MEK, anti-myc, or
anti-HA.
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FLAG-CNK2B (Fig. 5A). HA-ERK was immunoprecipi-
tated and assayed for activity. Overexpression of
CNK2B inhibited ERK activity in HEK293 cells. As an
alternative approach, we used ELK phosphorylation
and activation as a readout for MAPK pathway signal-
ing. This was accomplished by cotransfecting the Gal4
DNA binding site enhancer fused to the thymidine
kinase promoter-luciferase reporter gene (Gal4-luc)
and ELK-Gal4 DNA binding domain fusion protein
(ELK-Gal4) in the presence or absence of RasV12 and
either HA-CNK2 or HA-smgGDS in HEK293 cells (Fig.
5B). RasV12-stimulated ELK-Gal4 induced luciferase
activity by 12-fold. Overexpression of HA-CNK2A and
HA-CNK2B reduced RasV12 stimulation threefold and
twofold respectively. Overexpression of HA-CNK2-N-
term and an unrelated protein, HA-smgGDS, had no
effect on RasV12 stimulation of ELK-Gal4. As a control,
a Western blot shows similar amounts of CNK2 proteins
and smgGDS (Fig. 5B, inset).
To pursue these observations, we asked whether
CNK2 could mediate ErbB4-stimulated MAPK signal-
ing. ErbB4 receptor activity is regulated by PSD-95 via a
direct interaction in neurons (32). Since MAGUIN-1
was shown to interact with PSD-95 and is expressed
primarily in neurons, ErbB4 signaling may present a
better model for testing CNK2 function. Therefore,
FLAG-ERK1 was cotransfected with ErbB4, PSD-95,
HA-CNK2A, and HA-CNK2B as indicated (Fig. 5C).
ErbB4 receptor was stimulated with addition of neu-
regulin. Phosphorylation of immunoprecipitated ERK
was determined using anti-phospho-ERK antibody. The
amount of total ERK protein in the precipitates were
determined by Western blotting (Fig. 5C, lower panel).
Phosphorylated ERK was detected only upon stimula-
Figure 4. CNK2B-interacting domains of C-Raf. A) Schematic representation of the C-Raf and CNK2 deletion mutants. The
conserved domains are labeled and indicated by brackets and shaded areas. The amino acids corresponding to each construct
is shown on the left for the C-Raf constructs. B) Both FLAG-Raf-325-648 and FLAG-Raf-1-269 copurify HA-CNK2B. FLAG-C-Raf,
FLAG-Raf-325-648, or FLAG-Raf-1-269 deletion mutants were expressed in the presence or absence of HA-CNK2B in HEK293
cells for 48 h. HA-CNK2B was immunoprecipitated by anti-HA. The precipitates and cell lysis were resolved by SDS
polyacrylamide and immunoblotted with anti-FLAG and anti-Raf-1. FLAG-C-Raf and FLAG-Raf-1-269 were immunoblotted with
anti-Raf-1 and FLAG-Raf-325-648 with anti-FLAG. The immunoblot was then stripped and probed again with anti-HA. C) GST
fusion with the carboxyl-terminal construct of CNK2B (GST-CNK2B-C-term) was expressed with various HA-tagged C-Raf
constructs as in panel B. GST-CNK2B-C-term was pulled down by glutathione-coupled Sepharose beads. The pulled down
proteins and cell lysate were resolved and immunoblotted with anti-HA.
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tion with neuregulin, not in the absence of neuregulin.
Overexpression of CNK2A, but not CNK2B significantly
inhibited ERK phosphorylation. This may be due to the
selective ability of CNK2A to interact with PSD-95, as
reported for MAGUIN-1 by Yao et al. (21).
To address the biological function of CNK2, NIH3T3
cells were transfected with RasV12 in the presence or
absence of CNK2 and assayed for cell transformation
(data not shown). Surprisingly, overexpression of
CNK2A, CNK2B, or CNK2-N-term did not significantly
affect RasV12-induced foci formation. This indicates
that ERK activation in NIH3T3 cells is not significantly
inhibited by CNK2.
CNK2 interacts with Ras effector proteins Rlf,
but not PI3K
Genetic studies in Drosophila showed CNK mediates eye
development upon stimulation with the Ras effector
mutant RasV12G37 (17). It has been shown that
RasV12G37 acts by binding to RalGEFs. To test whether
CNK2 can interact with proteins in the Ral pathway,
coimmunoprecipitation studies were performed.
FLAG-CNK2B was expressed in HEK293 cells with
HA-Ral in the presence or absence of Ral stimulators
RasV12 and HA-Rlf. Immunoprecipitation of FLAG-
CNK2B weakly copurified HA-Ral in the presence of
RasV12 (Fig. 6A). Due to the weak nature of the
interaction, we are unable to determine whether the
interaction is dependent on Ras stimulation (compare
lanes 2 and 3). However, overexpression HA-Rlf does
not appear to affect the amount of HA-Ral pulled down
(compare lanes 3 and 4), suggesting that CNK2B-Ral
interaction is not mediated by Rlf as a bridge. To
further investigate the interaction between CNK2 and
Ral, coimmunoprecipitation experiments using rat
brain tissue were performed. Immunoprecipitation of
endogenous CNK2 copurified endogenous Ral protein
(Fig. 6B). As a control, anti-Tuberin, which does not
immunoprecipitate CNK2 (compare lanes 1 and 3),
does not copurify Ral. The anti-maguin N-term anti-
body should recognize both CNK2A and CNK2B. The
site-TK-luc reporter construct and Gal4 DNA binding do-
main–ELK fusion construct were cotransfected with RasV12,
CNK2 constructs and smgGDS in HEK293 cells in serum-free
media for 16 h. Cell extracts were assayed for luciferase and
-galactosidase activity. Transfection efficiencies were nor-
malized with the -galactosidase activity. Multiple experi-
ments were compared by normalization to the unstimulated
reporter. The amount of expression from the CNK2 con-
structs and smgGDS are shown (inset). C) CNK2A, but not
CNK2B, inhibits neuregulin (NRG) stimulation of ERK.
ErbB4 and FLAG-ERK1 are expressed with PSD-95, HA-
CNK2A, or HA-CNK2B. 24 h after transfection, cells were
starved with DMEM without serum for 6 h. Before cell lysis the
cells were stimulated in the presence or absence of neuregu-
lin (5 nM) for 10 min. FLAG-ERK was immunoprecipitated
from cell lysate by anti-FLAG and immunoblotted with an
anti-phospho-MAPK antibody. The amount of FLAG-ERK1
present in precipitates were immunoblotted with anti-ERK.
Figure 5. CNK2 inhibits the MAPK signaling pathway.
A) RasV12-stimulated ERK activity is inhibited in the pres-
ence of overexpressed CNK2B. myc-ERK is expressed in the
presence or absence of RasV12, increasing concentrations
of FLAG-CNK2B (50, 100, and 250 ng) in HEK293 cells for
24 h, and serum starved in 0.1% FBS for 16 h. HA-ERK was
immunoprecipitated by anti-HA and assayed for kinase
activity using GST-ELK1 as a substrate. Phosphorylation of
GST-ELK1 substrate is shown (top panel). The amount of
myc-ERK in precipitates were immunoblotted with anti-myc
(bottom panel). B) RasV12 induced luciferase activity is
inhibited by overexpressed CNK2B. Gal4 DNA binding
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multiple bands of CNK2 immunoprecipitated from
brain lysate with anti-Maguin N-term antibody are sim-
ilar to data described previously for immunoprecipita-
tion with maguin (21) and consistent with alternatively
spliced form of CNK2A and CNK2B (Fig. 1). These data
suggest the interaction between CNK2 and Ral is phys-
iologically relevant.
Next we asked whether CNK2B interacts with Rlf by
coimmunoprecipitation. FLAG-CNK2B was expressed
in HEK293 cells in the presence or absence of HA-Rlf.
HA-Rlf copurified with immunoprecipitated FLAG-
CNK2B but not unrelated proteins FLAG-SOS or FLAG-
FKHR (Fig. 6C). CNK2 interaction with Rlf was much
stronger than with Ral. Neither FLAG-CNK2-N-term
Figure 6. Ral signaling components coimmunoprecipitates with CNK2B and mapping of the CNK2B interaction domain of Rlf.
A) HA-Ral weakly coimmunoprecipitates with FLAG-CNK2B. HA-Ral was expressed in the presence or absence of FLAG-CNK2B,
RasV12, and HA-Rlf in HEK293 cells for 48 h. FLAG-CNK2B was immunoprecipitated with anti-FLAG. Precipitates and cell
lysates were resolved by a 15% SDS polyacrylamide gel and immunoblotted with anti-Ral. Cell lysate was resolved on a 10% SDS
polyacrylamide gel and immunoblotted with anti-FLAG. B) Endogenous CNK2 and Ral coimmunoprecipitate from rat brain
lysate. CNK was immunoprecipitated with anti-Maguin N-term, an antibody generated against the mouse homologue of CNK2.
The precipitates were resolved by a 15% SDS polyacrylamide gel and immunoblotted with either anti-Ral or anti-Maguin N-term.
C) HA-Rlf coimmunoprecipitates with FLAG-CNK2B. HA-Rlf was expressed in the presence and absence of FLAG-tagged
CNK2B, CNK2-amino-terminal construct (FLAG-N-term), SOS and FKHR as in panel A. The FLAG-tagged constructs were
immunoprecipitated with anti-FLAG. The precipitates and cell lysates were resolved as in panel A, and immunoblotted with
anti-HA. The blot was then stripped and reprobed with anti-FLAG. C) FLAG-CNK2B interacts with the GEF domain of Rlf.
FLAG-CNK2B was expressed in the presence or absence of HA-tagged Rlf constructs as in panel A. FLAG-CNK2B was
immunoprecipitated by anti-FLAG. The precipitates and cell lysates were resolved and immunoblotted as in panel B.
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(Fig. 6C) nor FLAG-CNK2B-C-term (data not shown)
copurified HA-Rlf, suggesting that the full-length mol-
ecule may be required. Furthermore, HA-Rlf can inter-
act with both FLAG-CNK2B and FLAG-CNK2A equally
well (data not shown). Last, HA-RalGDS, an Rlf homo-
logue, was also shown to copurify with FLAG-CNK2B,
suggesting that CNK2 may be important for general Ral
signaling (data not shown).
To map the CNK2 region of interaction within Rlf,
coimmunoprecipitation studies were performed by ex-
pressing deletion mutants of Rlf in the presence or
absence of FLAG-CNK2B in HEK293 cells. Immunopre-
cipitation of FLAG-CNK2B brought down the amino-
terminal half of Rlf (HA-Rlf-N-term), which contains
the GEF domain (Fig. 6D), but not the carboxyl-
terminal half (HA-Rlf-C-term) consisting of the Ras
binding domain (data not shown). HA-Rlf-N-term was
further divided into the GEF domain (HA-Rlf-GEF) and
the GEF amino-terminal-associating domain (HA-Rlf-
GN). These Rlf constructs were then tested for the
ability to interact with CNK2 by coimmunoprecipita-
tion experiments. HA-Rlf-GEF, but not HA-Rlf-GN,
copurifies with FLAG-CNK2B (Fig. 6D). These data
suggest that CNK2B specifically interacts with the GEF
domain of Rlf.
Since the Ras effector proteins Raf and Rlf both
interact with CNK2B, we tested whether the PI3K
subunits p110 and p85 could also interact with CNK2B
in coimmunoprecipitation experiments. Neither sub-
unit of PI3K, p85 ,or p110 could copurify with CNK2B
(data not shown). Hence, CNK2 can interact with only
a specific subset of Ras effector proteins.
CNK2 does not mediate Ral activity
Since CNK2 interacts with Ral signaling proteins, we
asked whether CNK2 mediates Ral signaling. HA-Ral
was transfected into HEK293 cells in the presence or
absence of RasV12, HA-CNK2A, and HA-Rlf (Fig. 7).
Ral-GTP was pulled out of the cell lysate with glutathi-
one-coupled agarose beads bound to GST-RalBP Ral
binding domain (RBD) fusion protein. RalBP-RBD has
been shown to specifically interact with activated Ral
(33). The amount of activated Ral pulled down was
then immunoblotted with anti-Ral. From this assay, it
appears that RasV12 can activate Ral only slightly, but
that overexpression of HA-Rlf in the presence of
RasV12 strongly activates Ral. Expression of HA-CNK2A
appears to have little or no effect on Ral activation in
the presence of RasV12 regardless of HA-Rlf expression
(Fig. 7). Similar results were observed even when the
expression level of Rlf was titrated down (data not
shown). These results suggest that overexpression of
CNK2A does not significantly affect Ral activation in
HEK293 cells.
To identify a functional consequence for the CNK2-
Rlf interaction, we asked whether CNK2B affected Rlf
localization in the cell. Since Rlf translocates from the
cytoplasm to the membrane upon activation, we used
cell fractionation experiments to test whether CNK2B
affects Rlf localization. HA-CNK2B and HA-Rlf were
expressed in HEK293 cells both independently and
together. The cells were lysed and membranes sepa-
rated from the cytosol by ultracentrifugation. Cell
cytosol and membranes were resolved and immuno-
blotted with anti-HA (Fig. 8). The amount of HA-Rlf in
cytosol vs. membrane remains unchanged when coex-
pressed with HA-CNK2B. Similarly, immunofluores-
cence experiments suggest that CNK2B or CNK2A do
not affect Rlf translocation in MDCK cells (data not
shown). Membrane localized HA-CNK2B appears to
increase in the presence of HA-Rlf. Overall, these data
suggest that CNK2B does not affect Rlf translocation to
the membrane but that Rlf may increase CNK2 mem-
brane localization.
Lateral localization of CNK2 in MDCK cells
MAGUIN has been shown to be membrane localized in
CHO and COS cells (20, 21). CNK was also membrane
localized but with predominate staining at the apical
portions of eye imaginal discs in Drosophila (15). To
assess CNK2 localization in polarized cells, stable cell
lines expressing relatively low levels of HA-CNK2 were
generated in MDCK cells. MDCK cells are derived from
kidney basement membrane cells that express several
PDZ-containing proteins. Both HA-CNK2A (Fig. 9A)
and HA-CNK2B (data not shown) are localized to the
lateral membrane but not at the apical portion of
MDCK cells, as determined by immunofluorescence
staining. Various HA-CNK2 constructs (see Fig. 1 and
Fig. 4A) were expressed in MDCK cells to map the
membrane localization region of CNK2. HA-CNK2B is
membrane localized even though the carboxyl termi-
Figure 7. Overexpression of CNK2A does not affect Ral
activation. HA-Ral was expressed in the presence or absence
of RasV12, HA-Rlf and HA-CNK2A in HEK293 cells for 16 h,
then grown-starved in 0.1% serum for 4 h prior to cell lysis.
Ral-GTP was pulled down from cell lysate by GST-RalBP-RBD
fusion protein immobilized to glutathione-coupled Sepha-
rose. The amount of Ral-GTP in the pull downs were resolved
by a 15% SDS polyacrylamide gel and immunoblotted with
anti-Ral. Cell lysates were immunoblotted with anti-HA for the
presence of expressed HA-Ral, HA-CNK2A, and HA-Rlf.
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nus PDZ binding site is not present in HA-CNK2A
(compare Fig. 9B, E). However, a deletion within the
PDZ domain of CNK2 results in more mislocalization of
HA-CNK2B than HA-CNK2A, although membrane lo-
calization still predominates with both (Fig. 9C, F).
Surprisingly, the amino-terminal and carboxyl-terminal
constructs of CNK2 are mislocalized from the lateral
membrane (Fig. 9D, G–I). It has been reported that the
carboxyl-terminal portion of MAGUIN is responsible
for plasma membrane localization in CHO cells (20).
Our data suggest that full-length CNK2 is required for
proper localization to the membrane. The PDZ binding
site and PDZ domain may play some role in membrane
localization.
DISCUSSION
We found that CNK2 interacts with downstream effec-
tors of Ras, including Raf and Rlf, but not PI3K. These
observations support a model that CNK2 acts as a
scaffold protein in Ras signaling. CNK2 interacts with
the GEF domain of Rlf and with both the regulatory
Figure 8. CNK2B does not affect Rlf localization. HA-
CNK2B and HA-Rlf were expressed independently and
together in HEK293 cells for 20 h. Cell lysates were
fractionated by ultracentrifugation, resolved by SDS poly-
acrylamide gel, and immunoblotted with anti-HA (upper
panel). As a control for membrane fractionation, the
immunoblot was stripped and reprobed for MEK, a cytoso-
lic localized protein (lower panel).
Figure 9. Localization of CNK2 and various constructs of CNK2 in MDCK cells. A) Confocal image of immunofluorescence
staining of CNK2A. Stable cell line of HA-CNK2A was generated and stained using an anti-HA primary antibody and a Texas
red-conjugated secondary antibody. Cross section view (Z-section) of the stained cells show lateral membrane staining (middle
panel). Staining of myc-PALS 1 as a control sample showing apical membrane localization (lower panel). myc-PALS 1 was stained
with anti-myc antibody (9E10) and an FITC-conjugated secondary antibody. B–I) Images of transient expression of HA-CNK2
and various constructs stained with an anti-HA primary antibody and a Texas red-conjugated secondary antibody. Shown are
CNK2A (B); CNK2B (E); the CNK2-N-term (H ); CNK2A, CNK2B, CNK2-N-term with a portion of the PDZ domain deleted by
alternative splicing (C, F, and I, respectively); and the CNK2A-C-term and CNK2B-C-term (D and G, respectively). Images were
taken with the 100 objective.
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and catalytic domains of Raf. The Raf interaction was
also mapped to the carboxyl-terminal half of CNK2.
Overexpression of CNK2 results in inhibition of the
MAPK signaling pathway. CNK2 is also phosphorylated
via components of the MAPK signaling pathway. How-
ever, CNK2 does not appear to alter the localization of
Raf (data not shown; see also ref 21) or Rlf in the cells.
Characterization of CNK2 membrane localization,
phosphorylation, and Raf interaction indicates that
CNK2 is a functional homologue of Drosophila CNK and
rat MAGUIN.
CNK2 is structurally conserved across species. CNK2
averages a 38% amino acid similarity to CNK across the
conserved domains and is nearly identical to the rat
MAGUIN-1 overall. The four putative protein–protein
binding domains SAM, CRIC, PDZ, and PH are con-
served in CNK2 and across species. The carboxyl-
terminal region of CNK2, which includes the PH do-
main, interacts with Raf kinase as does CNK and
MAGUIN. MAGUIN was shown to interact with the
kinase domain of Raf (21). Similarly, CNK2 interacts
with the Raf kinase domain. In addition, we observed
that CNK2 interacts with the regulatory domain of Raf.
The functional relevance for CNK2 to interact with
both the regulatory and catalytic domains of Raf kinase
is unclear. Unlike the tyrosine phosphorylation of CNK,
tyrosine phosphorylation of CNK2 is detected only in
the presence of tyrosine phosphatase inhibitors, sug-
gesting that tyrosine phosphorylation is weak or rapidly
turned over under physiological conditions. Further-
more, the MAPK signaling pathway appears to play a
role in CNK2 phosphorylation, since MEK inhibitor
reduces CNK2 phosphorylation in vivo. The role of
phosphorylation on CNK2 function is unknown, but
similar observations have been made with KSR, indicat-
ing a possible regulatory function. Phosphorylation of
KSR by c-TAK results in membrane localization of KSR
(34). A CNK loss-of-function allele was shown to con-
tain a point mutation in a putative SH2 domain binding
site, suggesting a possible role of phosphorylation in
CNK function (15). Taken together, the structural and
functional homology of CNK suggest a common role in
Ras signaling across species.
Localization to the plasma membrane also appears to
be an important characteristic of the CNK homologues.
However, the region responsible for membrane local-
ization of CNK2 and MAGUIN is unclear. It was re-
ported that the carboxyl-terminal region (without the
PH domain) of MAGUIN was sufficient for localization
to the membrane. However, in this report we show that
the carboxyl-terminal region (including the PH do-
main) of CNK2 is mislocalized from the lateral mem-
brane. In fact, our data suggest that full-length CNK2 is
required for proper lateral membrane localization,
with minor contributions from the PDZ domain and
the PDZ binding site in CNK2A. The differences in
observations may be due to expression of CNK2 and
MAGUIN constructs in different cell lines. The identity
of the lateral membrane subcellular site remains to be
determined. Based on the immunostaining in Fig. 9, it
appears that some of the CNK2 is cytoplasmic and
granular suggesting CNK2 may be localized to vesicles
or insoluble aggregates. Fractionation and solubiliza-
tion studies show that CNK2 is soluble, suggesting that
CNK2 may be sublocalized to cytoplasmic vesicles (data
not shown).
CNK2 interacts with the Ras effector protein Raf
kinase. The CNK-Raf interaction appears to be evolu-
tionarily conserved. Mammalian CNK2 interacts with
both C-Raf and B-Raf and Drosophila CNK interacts with
D-Raf. Although the interaction between CNK and Raf
has been shown mostly by coimmunoprecipitation ex-
periments, CNK and D-Raf were shown to interact in
the yeast two-hybrid system, indicating a direct interac-
tion between the proteins (15). MAGUIN was able to
coimmunoprecipitate endogenous Raf from brain tis-
sue, demonstrating the interaction in vivo (21). These
observations suggest that CNK2 may play some role in
Raf signaling. In agreement with this, overexpression of
CNK2 in HEK293 cells inhibits MAPK signaling path-
way. This may not reflect the physiological effects of
CNK2, since inhibition is seen only with very high levels
of CNK2 expression. A similar effect is seen with KSR,
in which overexpression inhibits Ras signaling in Dro-
sophila, Xenopus oocytes, and mammalian cells (22,
35–38), yet is proposed to act positively in the pathway.
Similar results have been observed with other known
scaffolding proteins. For example, overexpression of
JIP, a scaffold in the JNK pathway, can inhibit JNK
activation (39, 40), presumably by titrating out compo-
nents from the pathway. Overexpression of MP1 had
little effect on MAPK signaling except under specific
conditions of MP1, MEK, and ERK expression (14).
Knockdown of KSR or CNK in Drosophila S2 cells
inhibits MAP kinase activation, indicating that these
two scaffold proteins have a positive role in Ras signal-
ing (16, 41). Taken together, these data suggest that
CNK2 may play a positive role in MAPK signaling.
Genetic studies have suggested that CNK may mod-
ulate an additional Ras signaling pathway, possibly the
Ral pathway (17). Biochemically, we showed that CNK2
interacts with Rlf and Ral of the Ral pathway, suggesting
CNK2 may mediate both MAPK and Ral signaling in
some capacity. Basal levels of MAPK activity have been
shown to be required for Ral induction of F9 embry-
onic carcinoma cell differentiation (42). The mecha-
nism by which MAPK modulates Ral signaling is not
known. It is interesting to speculate that CNK2 may be
a contributing factor since it appears to be phosphory-
lated by the MAPK pathway and interacts with Ral
signaling components. Although CNK2 did not affect
GTP binding of Ral in HEK293 cells, this does not
necessarily rule out a role for CNK2 in Ral signaling.
Similar to overexpression of scaffold-like proteins KSR,
MP1, or CNK2 in MAPK signaling, overexpression of
CNK2 may not reveal its physiological role in Ral
signaling. Our finding that CNK2 interacts with com-
ponents of the Ral pathway supports the genetic studies
that CNK may positively regulate Ral signaling in Dro-
sophila eye development (17). However, it has been
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reported that the interplay between the Ras effector
pathways in Drosophila eye development is more com-
plex. For example, it has been reported that
RasV12G37 may actually promote the PI3 kinase path-
way (43). In another study, RasV12G37 interacts with
RGL (Drosophila RalGEF) but does not stimulate the Ral
pathway (44). Furthermore, genetic interactions be-
tween the Ras and Ral pathways in Drosophila do not
support a simple linear pathway model (44). In light of
these observations, it is interesting that CNK2 interacts
with both Raf and Rlf. It is possible that CNK2 may
integrate signals between MAPK and Ral pathways in a
complex interplay of components. Also, neural-specific
expression of CNK2, as determined with MAGUIN-1
(20), suggests a possible mechanism by which ubiqui-
tous pathways elicit cell-specific responses.
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